Carbazilquinone (Carboquone)

An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.

Also Known As:

Networked: 134 relevant articles (13 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ikehata, Masateru: 1 article (09/2006)
2.	Miyakoshi, Yuichi: 1 article (09/2006)
3.	Shimizu, Hidesuke: 1 article (09/2006)
4.	Suzuki, Yuji: 1 article (09/2006)
5.	Toyama, Yoshimitsu: 1 article (09/2006)
6.	Yoshioka, Hayato: 1 article (09/2006)
7.	Koh, Masae: 1 article (12/2003)
8.	Morimoto, Ken: 1 article (12/2003)
9.	Begleiter, A: 1 article (11/2000)
10.	Hatake, K: 1 article (07/2000)

Related Diseases

1.	Neoplasms (Cancer) 02/01/1984 - "Based on these effects of antibody on tumor cell growth, sequential administration of antibody followed by an anticancer drug (carboquone) was proven to be the most effective immunochemotherapeutic schedule for tumor bearing rats, showing 25-33% long-term survival in comparison with any other controls." 04/01/1981 - "Effect of alternating administration of PS-K and carbazilquinone in tumor-bearing mice." 11/01/1974 - "[Absorption, distribution, excretion and metabolism of carbazilquinone; a new anti-tumor agent, in mice (author's transl)]." 12/01/1970 - "Effect of carbazilquinone on transplantable and primary tumors in mice." 09/01/1983 - "[Fundamental studies on intravesical instillation of carboquone for treatment of urinary bladder tumors--on the effects of intravesical instillation of carboquone in normal beagle dogs]."
2.	Urinary Bladder Neoplasms (Bladder Cancer) 01/01/1981 - "On the results of tests performed to establish the drug concentration required to achive a 50% inhibition of cell survival, carbazilquinone was chosen for the prevention of recurrences of bladder cancer. " 07/01/1979 - "Prophylactic effects of periodic intravesical Carboquone were also indicated in 7 of 8 patients who had experienced recurring superficial bladder tumors." 05/01/1977 - "[Chemotherapy of bladder neoplasms--instillation of carboquone into the bladder]." 01/01/1981 - "Anticancer drug sensitivity in vitro in the bladder cancer cell line, KK-47 and prophylactic use of carbazilquinone and urokinase in bladder cancer." 09/01/1983 - "Eleven months later, bladder cancer was found and treated with TUR-Bt (Transitional cell carcinoma, G2, PTlmNXMO ) followed by intravesical instillation of carboquone and adriamycin. "
3.	Colorectal Neoplasms (Colorectal Cancer) 08/01/1991 - "Sarcoma-180 cells and human colorectal tumor cells under in vitro hypoxic conditions are more sensitive to mitomycin C and carboquone." 08/01/1991 - "The effects of oxygen concentration on the chemosensitivity of mouse sarcoma-180 (S-180) cells and human colorectal cancer tissues to mitomycin C (MMC) or carboquone (CQ) were determined in vitro, since evidence had been obtained that these drugs are more effective in HeLa cells. " 05/01/1998 - "The results of the chemosensitivity assay are as follows: 5-FU seems to be the most beneficial for primary colorectal cancer; carboquone (CQ), etoposide (VP-16), 5-FU, and mitomycin-C (MMC) for nodal metastasis; CQ, cisplatin (CDDP), 5-FU, adriamycin (ADR) and VP-16 for malignant effusion; and VP-16, CDDP and CQ for liver metastasis. " 05/01/1986 - "Among 9 chemotherapeutic drugs tested, ara-C, 5-fluorouracil, and mitomycin C showed the high percentages of positive sensitivity for gastric cancer, whereas actinomycin D, carboquone, and nimustine hydrochloride were sensitive in case of colorectal cancer. " 04/01/1986 - "Among 9 chemotherapeutic agents tested, ara-C, 5-fluorouracil, and mitomycin C had higher percentages of positive sensitivity for stomach cancer, whereas actinomycin D, carboquone, and ACNU had a more pronounced effect on colorectal cancer. "
4.	Stomach Neoplasms (Stomach Cancer) 03/01/1982 - "However, it was as sensitive to Carboquone as high-sensitive gastric cancer cell lines. " 09/01/1987 - "A randomized controlled study was carried out on curatively resected gastric cancer patients in a cooperative study involving 16 institutions in order to evaluate the effect of an alternative long-term adjuvant immunochemotherapy using Esquinon (CQ) and Krestin (PSK). " 02/01/1986 - "[Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. " 08/01/1988 - "In 8 cases of advanced and/or relapsed gastric cancer (7 cases advanced, 1 case relapsed), we undertook combination chemotherapy with systemic administration of cisplatin and celiac arterial infusion of carboquone intermittently under continuous administration of OK-432 i.m. " 08/01/1988 - "[Clinical study of combination chemotherapy using carboquone, cisplatin, UFT and OK-432 in 7 cases of advanced gastric cancers and a relapsed gastric cancer]."
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/01/1978 - "[Studies of carboquone therapy on chronic myelogenous leukemia (author's transl)]." 10/01/1982 - "A daily oral dose of 1-2 mg of Carboquone was administered for remission induction to 38 patients with hematologic malignancy, and the following results were obtained: 2 of the 3 patients with malignant lymphoma, 1 of the 12 patients with multiple myeloma, 13 of the 14 patients with chronic myelogenous leukemia, and all 9 patients with polycythemia vera attained complete remission."

Related Drugs and Biologics

1.	Mitomycin (Mitomycin-C)
2.	Doxorubicin (Adriamycin)
3.	Fluorouracil (Carac)
4.	Bleomycin (Blenoxane)
5.	Cisplatin (Platino)
6.	Cyclophosphamide (Cytoxan)
7.	Picibanil
8.	Chromomycin A3
9.	Thiotepa (Triethylenethiophosphoramide)
10.	Tegafur

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Intravesical Administration
4.	Remission Induction
5.	Combination Drug Therapy (Combination Chemotherapy)